Parallax Volatility Advisers
PGNX

Parallax Volatility Advisers’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Parallax Volatility Advisers’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-478,657
Closed -$2.01M – 4462
2018
Q4 		$2.01M Buy
478,657
+27,823
+6% +$142K ﹤0.01% 1061
2018
Q3 		$2.83M Buy
+450,834
New +$3.46M ﹤0.01% 914
2018
Q2 		– Sell
-1,959
Closed -$15K – 3722
2018
Q1 		$15K Sell
1,959
-8,793
-82% -$58.5K ﹤0.01% 1762
2017
Q4 		$64K Buy
10,752
+8,793
+449% +$53.4K ﹤0.01% 3079
2017
Q3 		$14K Buy
+1,959
New +$12.4K ﹤0.01% 1729

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Parallax Volatility Advisers's PGNX Position: Q1 2019 in Review

Parallax Volatility Advisers sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2019, closing a stake of 478,657 shares — an estimated $2.01M sold.

Parallax Volatility Advisers first reported a position in PGNX in Q3 2017 and held it in 5 quarters. The position peaked at $2.83M in Q3 2018. 148 funds tracked by Wall St. Rank hold PGNX as of Q1 2019.

  • Parallax Volatility Advisers reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 478,657 Progenics Pharmaceuticals Inc shares in Q1 2019, an estimated $2.01M.
  • Parallax Volatility Advisers first reported a position in Progenics Pharmaceuticals Inc in Q3 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Progenics Pharmaceuticals Inc position peaked at $2.83M in Q3 2018.
  • 148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2019.

Based on Parallax Volatility Advisers's 13F filing for Q1 2019, filed 15 May 2019.